Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 | P23458 | 1/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.53 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.51 |
| ▸ | KCNN3 | Q9UGI6 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 3/20 | 0.48 |
| ▸ | RAB9A | P51151 | 3/20 | 0.48 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL382481 | 0.98 | JAK1 (0.54) | JAK1KCNH2HDAC6KCNN3SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL8130344 | 0.97 | JAK1 (0.53) | JAK1KCNH2HDAC6KCNN3SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL5007369 | 0.97 | JAK1 (0.53) | JAK1KCNH2HDAC6KCNN3SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL9691036 | 0.92 | NPC1 (0.50) | JAK1KCNH2HDAC6KCNN3SMN1; SMN2 | |
| SCHEMBL9690640 | 0.90 | CHEK1 (0.52) | JAK1KCNH2HDAC6KCNN3SMN1; SMN2 | |
| SCHEMBL28406604 | 0.89 | HDAC6 (0.57) | KCNH2HDAC6KCNN3SMN1; SMN2NPC1 | |
| Hydrochloric Acid SCHEMBL9691095 | 0.88 | CHEK1 (0.51) | JAK1KCNH2HDAC6KCNN3SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL9690626 | 0.88 | CHEK1 (0.51) | JAK1KCNH2HDAC6KCNN3SMN1; SMN2 | |
| Propionic Acid SCHEMBL28749715 | 0.86 | SMN1; SMN2 (0.53) | JAK1KCNH2SMN1; SMN2NPC1RAB9A | |
| SCHEMBL27898220 | 0.86 | RIPK1 (0.62) | HDAC6KCNN3SMN1; SMN2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7528149-B2 | Respiratory syncytial virus replication inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-05-05 | — | — | US | disclosed |
| US-7407969-B2 | Respiratory syncytial virus replication inhibitors | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-08-05 | — | — | US | disclosed |
| US-7390811-B2 | Respiratory syncytial virus replication inhibitors | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-06-24 | — | — | US | disclosed |
| US-7361657-B2 | Respiratory syncytial virus replication inhibitors | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-04-22 | — | — | US | disclosed |
| US-20070135404-A1 | Respiratory Syncytial Virus Replication Inhibitors | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-06-14 | — | — | US | disclosed |
| EP-1400519-B1 | Respiratory syncytial virus replication inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2007-03-07 | — | — | EP | disclosed |
| US-7179811-B2 | Respiratory syncytial virus replication inhibitors | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-02-20 | — | — | US | disclosed |
| US-7173054-B2 | Respiratory syncytial virus replication inhibitors | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-02-06 | — | — | US | disclosed |
| US-7173034-B2 | Respiratory syncytial virus replication inhibitors | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-02-06 | — | — | US | disclosed |
| US-20070021410-A1 | Respiratory syncytial virus replication inhibitors | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-01-25 | — | — | US | disclosed |
| WO-2001000615-A1 | RESPIRATORY SYNCYTIAL VIRUS REPLICATION INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2001-01-04 | — | — | WO | disclosed |
| WO-2001000612-A2 | RESPIRATORY SYNCYTIAL VIRUS REPLICATION INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2001-01-04 | — | — | WO | disclosed |
| WO-2001000611-A1 | RESPIRATORY SYNCYTIAL VIRUS REPLICATION INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2001-01-04 | — | — | WO | disclosed |
| EP-0378254-B1 | 2-Aminopyrimidinone derivatives | JANSSEN PHARMACEUTICA NV (BE) | 1994-06-22 | — | — | EP | disclosed |
| EP-0282133-B1 | 1-ALKYL SUBSTITUTED BENZIMIDAZOLE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 1993-07-28 | — | — | EP | disclosed |
| EP-0232937-B1 | ANTI-HISTAMINIC COMPOSITIONS CONTAINING N-HETEROCYCLYL-4-PIPERIDINAMINES | JANSSEN PHARMACEUTICA N.V. (BE) | 1992-08-19 | — | — | EP | disclosed |
| US-5008268-A | Antiallergens | JANSSEN PHARMACEUTICA N.V. (BE) | 1991-04-16 | — | — | US | disclosed |
| US-4943580-A | ANTIALLERGENS | JANSSEN PHARMACEUTICA N.V. (BE) | 1990-07-24 | — | — | US | disclosed |
| EP-0378254-A2 | 2-Aminopyrimidinone derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 1990-07-18 | — | — | EP | disclosed |
| EP-0282133-A2 | 1-alkyl substituted benzimidazole derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 1988-09-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135404-A1 | Respiratory Syncytial Virus Replication Inhibitors | SARS1, ACE, MAVS | JAK1 2505/4885KCNH2 4500/4885HDAC6 3826/4885 |
| US-20070021410-A1 | Respiratory syncytial virus replication inhibitors | CCNA1, CCNB3, CCNI | JAK1 906/4885KCNH2 1071/4885HDAC6 2243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.